Sarepta Therapeutics Inc. (SRPT)
NASDAQ:SRPT
Want to see SRPT full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.22Last Year’s EPS
1.89Same Quarter Last Year
Based on 24 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely constructive tone: Sarepta reported profitable Q1 results, strong gross margins, and a $748M cash balance while reiterating full-year guidance of $1.2B–$1.4B. The company highlighted meaningful clinical progress—notably robust early siRNA data (FSHD, DM1), encouraging EMBARK 3‑year and MRI evidence for Alevitus, regulatory progress with sNDA submissions, and commercialization initiatives (expanded sales force). Offsetting these positives were lower Alevitus product sales driving a modest YoY revenue decline (–2%), an information gap slowing demand recovery, short-term cash outflows tied to planned Arrowhead payments, and unresolved safety/regulatory uncertainty for non‑ambulatory Alevitus use that depends on small open‑label cohorts. Overall, the call emphasized stabilization and long‑term opportunity but signaled that commercial recovery for Alevitus will be gradual and that some clinical/regulatory risks remain.Company Guidance
Profitability and Strong Operating Performance
Reported GAAP operating profit of $358 million and non-GAAP operating profit of $398 million in Q1 2026, reflecting a profitable base business and positive cash flow excluding Arrowhead-related payments.
Solid Cash Position and Funding Capability
Ended the quarter with approximately $748 million in cash and investments; management states they can fully fund pipeline programs (DM1, FSHD, Huntington's, SCA2, IPF and preclinical portfolio) without accessing the equity markets.
Revenue and Product Mix
Total revenues for Q1 were $731 million (down 2% year-over-year). Net product revenue was $331 million, comprised of $229 million from PMO therapies (EXONDYS, VYONDYS, AMONDYS) and $102 million from Alevitus.
Improved Gross Margins and Lower Cost of Sales
Total cost of sales decreased to $109 million (a 21% decline versus prior year) and unit gross margins were reported at 82%, reflecting favorable margin dynamics on product sales.
Advancing siRNA Portfolio with Encouraging Early Data
Early Phase 1/2 data for SRP-1001 (FSHD) and SRP-1003 (DM1) showed dose-dependent plasma exposure, superior muscle delivery via the alpha v beta 6 integrin-targeting ligand, robust target engagement (DUX4-related gene suppression and DMPK knockdown), rapid reduction in CK (FSHD), and favorable repeated-dosing safety (no anemia); MAD cohort readouts expected later this year.
Alevitus Clinical Evidence and Real-World Experience
Alevitus has been administered to more than 1,300 patients (clinical and commercial). EMBARK trial shows meaningful and growing benefit through year three on multiple measures; muscle MRI data support reduced muscle loss and fat/fibrotic replacement. ENDEAVOR real-world interim data and physician experience suggest sirolimus pretreatment may mitigate liver enzyme elevations.
Regulatory and Value-Building Milestones
Submitted sNDAs (April) seeking conversion of AMONDYS 45 and 53 (PMOs) from accelerated to traditional approval following ESSENCE confirmatory data and supporting real-world evidence; Roche-related non-cash collaboration revenue of $325 million recognized this quarter and $40 million milestone from first commercial sale of Alevitus in Japan also recorded.
SRPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SRPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $23.03 | $20.80 | -9.68% |
Feb 25, 2026 | $18.97 | $17.45 | -8.01% |
Nov 03, 2025 | $24.45 | $16.20 | -33.74% |
Aug 06, 2025 | $16.26 | $17.96 | +10.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sarepta Therapeutics Inc. (SRPT) report earnings?
Sarepta Therapeutics Inc. (SRPT) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Sarepta Therapeutics Inc. (SRPT) earnings time?
Sarepta Therapeutics Inc. (SRPT) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRPT EPS forecast?
SRPT EPS forecast for the fiscal quarter 2026 (Q2) is 0.22.
